1800-272-662
Shopping Cart 0
countryflagAU
Login

Proteomics International Laboratories Ltd

Healthcare AU PIQ

0.32AUD
-0.02(5.88%)

Last update at 2026-03-13T05:10:00Z

Day Range

0.320.34
LowHigh

52 Week Range

0.280.86
LowHigh

Fundamentals

  • Previous Close 0.34
  • Market Cap56.16M
  • Volume123037
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-9.51176M
  • Revenue TTM3.21M
  • Revenue Per Share TTM0.02
  • Gross Profit TTM 0.46M
  • Diluted EPS TTM-0.07

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -8.15450M -8.63819M -6.23431M -4.97296M -2.85966M
Minority interest 0.04M 0.11M - - -
Net income -8.11480M -6.37622M -6.23431M -4.97296M -2.85966M
Selling general administrative 6.17M 5.55M 5.11M 4.36M 2.87M
Selling and marketing expenses - -3.82797M - 0.12M 0.06M
Gross profit 0.96M -1.12319M -1.61511M -0.56862M 0.50M
Reconciled depreciation 0.62M 0.73M 0.53M 0.42M 0.37M
Ebit -10.61872M -9.12477M -8.82815M -4.97251M -2.85956M
Ebitda -9.99601M -8.39708M -8.29862M -4.55565M -2.48704M
Depreciation and amortization 0.62M 0.73M 0.53M 0.42M 0.37M
Non operating income net other - - - - -
Operating income -10.61872M -9.12477M -6.36560M -4.97728M -3.08268M
Other operating expenses 11.58M 10.51M 4.86M 4.29M 3.98M
Interest expense - 0.02M - 0.00045M 0.00010M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.20M 0.28M 0.14M 0.00544M 0.01M
Net interest income 0.16M 0.26M 0.14M 0.00275M 0.00805M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -2.15638M -0.14836M 1.94M 1.64M
Total revenue 0.96M 0.89M 0.73M 1.49M 1.31M
Total operating expenses 11.58M 8.49M 9.55M 8.41M 5.82M
Cost of revenue - 2.02M 2.35M 2.06M 0.81M
Total other income expense net 2.46M 0.49M 2.45M 1.94M 1.64M
Discontinued operations - - - - -
Net income from continuing ops -8.15450M -6.48181M -6.23431M -4.97296M -2.85966M
Net income applicable to common shares -8.11480M -6.37622M -6.17657M -4.97296M -2.85966M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 14.78M 10.88M 10.08M 5.40M 8.60M
Intangible assets 0.00101M 0.00101M 0.00101M 0.00101M 0.00101M
Earning assets - - - - -
Other current assets 2.24M 0.12M 1.97M 1.73M 1.30M
Total liab 1.81M 1.63M 1.75M 2.00M 0.99M
Total stockholder equity 13.17M 9.41M 8.38M 3.39M 7.61M
Deferred long term liab - - - - -
Other current liab 1.12M 0.50M 0.55M 1.18M 0.30M
Common stock 47.64M 36.81M 30.18M 19.34M 19.10M
Capital stock 47.64M 36.81M 30.18M 19.34M 19.10M
Retained earnings -37.78583M -29.67104M -23.62758M -17.63007M -12.65711M
Other liab - - - 0.30M 0.21M
Good will - - - - -
Other assets - 0.00000M 0.06M 0.06M 0.00000M
Cash 11.04M 6.64M 6.03M 2.11M 5.60M
Cash and equivalents - - 5.79M 1.00M 5.05M
Total current liabilities 1.44M 0.90M 1.10M 1.70M 0.78M
Current deferred revenue 0.17M 0.25M 0.37M 0.36M 0.27M
Net debt -10.75908M -6.32385M -5.96323M -2.11151M -5.53579M
Short term debt 0.15M 0.10M 0.03M -0.35598M 0.07M
Short long term debt - - - - -
Short long term debt total 0.28M 0.32M 0.06M 0.06M 0.07M
Other stockholder equity - - -6.55268M -1.71084M -6.43812M
Property plant equipment - - 1.69M 0.97M 1.26M
Total current assets 13.52M 9.16M 8.33M 4.36M 7.34M
Long term investments - - - - -
Net tangible assets - - - 3.39M 7.61M
Short term investments - - - - -
Net receivables 0.24M 2.41M 0.21M 0.44M 0.30M
Long term debt - - - - -
Inventory - - 0.12M 0.08M 0.13M
Accounts payable - 0.06M 0.15M 0.52M 0.14M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 3.32M 2.27M 1.83M 1.68M 1.17M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - -0.00000M 0.06M 0.06M -1.26180M
Deferred long term asset charges - - - - -
Non current assets total 1.26M 1.71M 1.75M 1.03M 1.26M
Capital lease obligations 0.28M 0.32M 0.06M - 0.07M
Long term debt total - - 0.03M 0.00000M 0.00000M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -0.02965M -0.38802M -1.16513M -0.12946M -0.19100M
Change to liabilities - - 0.00000M 1.01M -0.14885M
Total cashflows from investing activities -0.02965M -0.38802M -1.16513M -0.12946M -0.19100M
Net borrowings - - - -0.06905M -0.06380M
Total cash from financing activities 11.03M 6.59M 10.77M 0.18M 5.64M
Change to operating activities - - - -0.36195M 0.04M
Net income -8.11480M -6.37622M -6.17657M -4.97296M -2.85966M
Change in cash 4.40M 0.61M 3.92M -3.49332M 3.24M
Begin period cash flow 6.64M 6.03M 2.11M 5.60M 2.37M
End period cash flow 11.04M 6.64M 6.03M 2.11M 5.60M
Total cash from operating activities -6.60434M -5.59315M -5.69291M -3.53996M -2.20907M
Issuance of capital stock 11.20M 6.63M 10.84M 0.25M 5.70M
Depreciation - 0.73M 0.53M 0.42M 0.37M
Other cashflows from investing activities 0.00000M 0.02M 0.05M 0.00000M 0.01M
Dividends paid - - - - -
Change to inventory - - 0.66M -0.64358M 0.11M
Change to account receivables - -0.03853M 0.29M -0.13908M 0.06M
Sale purchase of stock 11.20M 6.63M 10.84M 0.25M 5.70M
Other cashflows from financing activities -0.17256M -0.03534M -0.06551M -0.31419M -0.06380M
Change to netincome - - 0.32M 0.51M 0.32M
Capital expenditures 0.03M 0.40M 1.22M 0.13M 0.21M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.23M -0.66940M 0.29M -0.13908M 0.06M
Stock based compensation - 0.78M 0.32M 0.51M 0.33M
Other non cash items -6.60434M 0.72M -0.04587M 1.02M 0.28M
Free cash flow -6.63399M -5.99640M -6.91082M -3.66942M -2.41424M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PIQ
Proteomics International Laboratories Ltd		 -0.02 5.88% 0.32 - - 17.52 7.43 54.05 -19.4827
CSL
CSL Ltd		 -0.01 0.0071% 141.03 16.27 19.23 4.44 2.61 3.90 11.73
TLX
TELIX Pharmaceuticals Ltd		 0.06 0.53% 11.29 - 1111.11 4.73 6.52 3.77 86.30
MSB
Mesoblast Ltd		 -0.03 1.40% 2.11 - 454.55 41.58 3.42 30.11 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.19 1.59% 11.76 51.13 44.25 23.04 4.47 18.83 55.27

Reports Covered

Stock Research & News

View All

Profile

Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company's products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, which has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment. It is also developing diagnostic tests for that includes DKD - T1D, that is under clinical phase for type 1 diabetes, diabetic retinopathy, and diabetic neuropathy; Asthma and COPD, which has completed proof-of-concept study trials for asthma and chronic obstructive pulmonary disease; Plant Dieback, that is under development phase for phytophthora dieback; Diabetic Retinopathy, which has completed discovery phase for sight-threatening retinopathy; and Diabetic Neuropathy, that is under research phase to investigate predictive biomarkers for diabetic neuropathy. The company also offers analytical services, such as specialist contract research focusing on biomarker discovery, biosimilars quality control, and pharmacokinetic testing for clinical trials. It has strategic collaboration with Harry Perkins Institute of Medical Research, Bioplatforms Australia, The University of Western Australia, Australian Research Council Training Centre, and the Australian Centre. Proteomics International Laboratories Ltd was founded in 2001 and is based in Perth, Australia.

Proteomics International Laboratories Ltd

QEII Medical Centre, Perth, WA, Australia, 6009

Key Executives

Name Title Year Born
Dr. Richard John Lipscombe M.A., MA (Oxford), Ph.D., Ph.D., (London) Co-Founder, MD & Director NA
Ms. Jacqueline Gray Chief Financial Officer NA
Mr. Vikesh Malik Chief Commercialisation Officer NA
Mr. John Chuck Morrison Head of Bus. Devel. NA
Dr. Scott Bringans Head of Research NA
Dr. Pearl Tan Head of Logistics NA
Dr. Kirsten Peters Head of Clinical Studies NA
Ms. Karen Teresa Logan B.Com., FCIS, BCom, DipAppCorpGov, FFin, ACIS, AGI Company Sec. NA
Mr. John Chuck Morrison Head of Business Development NA
Ms. Karen Teresa Logan ACIS, B.Com., BCom, DipAppCorpGov, F Fin, FCIS, FC Company Secretary NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.